Payment overview · 2025
General Payments
$256.20
12 reported records · 8 companies
Healthcare provider profile · identity verified
Francis Royce Constantine, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW HARTFORD, NY · NPI 1457340432
Verified facts
What the public records show
CMS Open Payments records show Francis Royce Constantine, MD received $256.20 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.04 | 27.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.76 | 17.5% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $31.66 | 12.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.17 | 11.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.56 | 10.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.35 | 9.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.44 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.22 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.20 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.76 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $31.66 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 653 | 164 |
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 161 |
| Metoprolol Succinate | Metoprolol Succinate | 394 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 102 |
| Losartan Potassium | Losartan Potassium | 360 | 94 |
| Lisinopril | Lisinopril | 354 | 92 |
| Jardiance | Empagliflozin | 259 | 52 |
| Omeprazole | Omeprazole | 255 | 72 |
| Metformin Hcl | Metformin Hcl | 251 | 69 |
| Metformin Hcl Er | Metformin Hcl | 242 | 62 |
| Simvastatin | Simvastatin | 204 | 54 |
| Sertraline Hcl | Sertraline Hcl | 181 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 37 |
| Eliquis | Apixaban | 163 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 40 |
| Potassium Chloride | Potassium Chloride | 150 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 36 |
| Lovastatin | Lovastatin | 138 | 34 |
| Gabapentin | Gabapentin | 131 | 35 |
| Alendronate Sodium | Alendronate Sodium | 130 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 37 |
| Famotidine | Famotidine | 121 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 39 |
| Synthroid | Levothyroxine Sodium | 108 | 26 |
| Furosemide | Furosemide | 107 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 28 |
| Ezetimibe | Ezetimibe | 104 | 29 |
| Valsartan | Valsartan | 85 | 21 |
| Irbesartan | Irbesartan | 82 | 22 |
| Januvia | Sitagliptin Phosphate | 81 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 13 |
| Allopurinol | Allopurinol | 76 | 21 |
| Glipizide | Glipizide | 76 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 66 | 16 |
| Xarelto | Rivaroxaban | 63 | 15 |
| Torsemide | Torsemide | 57 | 13 |
| Farxiga | Dapagliflozin Propanediol | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 15 |
| Baclofen | Baclofen | 55 | 19 |
| Carvedilol | Carvedilol | 54 | 17 |
| Glimepiride | Glimepiride | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 13 |
| Montelukast Sodium | Montelukast Sodium | 50 | 13 |
| Ozempic | Semaglutide | 50 | 11 |
| Buspirone Hcl | Buspirone Hcl | 48 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Ramipril | Ramipril | 46 | 11 |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Glipizide Er | Glipizide | 44 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Prednisone | Prednisone | 43 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 13 |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Alprazolam | Alprazolam | 37 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 18 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Atenolol | Atenolol | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 21 |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Nateglinide | Nateglinide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | 11 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.20 · 12 records | PFIZER INC. | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, SPRAVATO, SUBLOCADE, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error